STAT

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

No dejes de visitar la web del podcast y apoyar a su creador: soundcloud.com

Autor

STAT

Categoría

Business

Web del podcast

soundcloud.com

Último episodio

13 de nov. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android 10 M+ de descargas · valoración de 4,7+ iOS muy pronto

Episodios

Episode 150: Ashish Jha on Covid-19 optimism, plus pharma cooperation, & the next pandemic phase 04.03.2021

We discuss Merck's decision to help Johnson & Johnson manufacture vaccine doses and whether it'll be a turning point for the drug industry or a relic of Covid-19 history. Then, as we near the one-year anniversary of the pandemic, STAT's Andrew Joseph joins us to explain what experts think is in store in the months and years to come. Finally, Ashish Jha, dean of Brown University’s School of Public...

Episode 149: Nancy Goodman on Covid vaccines for kids, & Greg Zuckerman on Novavax's remarkable rise 25.02.2021

First, pediatric cancer advocate Nancy Goodman joins us to discuss why she believes Covid-19 vaccine trials need to be sped up for teens and children. Then, Wall Street Journal reporter Greg Zuckerman calls in to explain the unlikely story behind Novavax, a former biotech penny stock now on the verge of making history. Finally, we embark on a lightning round, featuring quick takes on the confirmat...

Episode 148: Akshay Sharma on gene therapy's setback, biotech's brashest VCs, & the FDA's future 18.02.2021

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a significant setback for Bluebird Bio’s gene therapy program with some help from Akshay Sharma, a bone marrow transplant expert at St. Jude Children’s Research Hospital. Then, STAT's Kate Sheridan joins us to discuss her deep dive into Flagship Pioneering, the superlatively successful and fr...

Episode 147: David Fajgenbaum on Covid-19 drugs, the state of the pandemic, & meme biotech stocks 11.02.2021

When will we have enough vaccine doses? How many effective Covid-19 drugs are just waiting to be found? And what do Redditors think about biotech? We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we check in with our colleague Helen Branswell for her view on the current state of the Covid-19 pandemic and the ongoing vaccine rollout. Then, we're joined by...

Episode 146: Paul Offit on vaccine data, 23andMe is going public, & Merck's CEO is retiring 04.02.2021

We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we recap a busy week of news, featuring 23andMe's move to go public through a blank-check company, Merck CEO Ken Frazier's retirement after three decades at the drug maker, and how the future of Biogen’s Alzheimer’s disease drug got a little more complicated. Then, Paul Offit, director of the Vaccine Educa...

Episode 145: Kevin Davies on the CRISPR boom, & Megan Ranney on scientific misinformation 28.01.2021

First, we discuss the implications of Johnson & Johnson’s any-day-now data on a one-shot vaccine for Covid-19. Then, Kevin Davies, executive editor of the CRISPR Journal, joins us to talk about the strange boom in genome editing stocks and the future of the revolutionary technology. Finally, we talk to Megan Ranney, an emergency room physician and Brown University professor, about the challenges o...

Episode 144: Remembering STAT's Sharon Begley 22.01.2021

We're spending this entire episode remembering Sharon Begley, our revered and beloved colleague who died last week from complications of lung cancer. First, STAT's Eric Boodman joins us to discuss Sharon's path-breaking career and what he learned from reporting out her obituary. Then, a trio of STAT editors call in to talk about what it was like to work with Sharon, and we hear from number of her...

Episode 143: #JPM21: Déjà vu in Alzheimer's research, and OWS's legacy 14.01.2021

We're devoting this episode to the news coming out of the just-concluded J.P. Morgan Healthcare Conference, the drug industry's largest annual meeting. First, we'll dissect Eli Lilly's surprising data on a new Alzheimer's disease treatment and dig into its implications for the field. Then, we discuss whether there's a bubble inflating in the genome editing world, debate who will run the FDA under...

Episode 142: Bob Nelsen on the pandemic's next phase, plus Biden's biopharma plans & a CES preview 07.01.2021

On this year's first episode, STAT Washington correspondent Lev Facher joins us to break down the implications of a Democrat-controlled Senate. Then, our colleague Erin Brodwin calls in to talk about CES, the massive tech conference taking place next week. Finally, we chat with Bob Nelsen, a biotech venture capitalist and one of the few people who saw the coming pandemic with clarity months before...

Episode 141: Moderna's vaccine milestone, Warp Speed's hurdles, and biotech in 2021 18.12.2020

It's the final episode of 2020. We dig into the second vaccine that's been recommended by a panel of FDA advisors, and look ahead to see what's in store for biotech in 2021.

Episode 140: Pfizer's Covid-19 vaccine — the debate, details, and distribution 11.12.2020

Are Covid-19 vaccines safe for teens? Is the U.S. taking too long to authorize one? And how do you prepare for an FDA grilling?

Episode 139: Angela Rasmussen on AstraZeneca's confusing data, & Adam Koppel on biotech in 2021 03.12.2020

Can too much Covid-19 vaccine be a bad thing? Is biotech in a bubble? And how do you make blind mice see again?

Episode 138: The latest Covid-19 vaccine, Biden's pandemic plans, and Bill Gates unfiltered 19.11.2020

How do we measure whether Covid-19 vaccines work? What does Joe Biden think of the drug industry? And does Anthony Fauci think about retirement?

Episode 137: Natalie Dean on Pfizer's Covid-19 vaccine, plus the FDA's Alzheimer's quandary 12.11.2020

How well does Pfizer's Covid-19 vaccine work? What's the difference between efficacy and effectiveness? And should the FDA approve Biogen's Alzheimer's drug?

Bracing for a pandemic winter, Biogen's fortune at the FDA, and remembering a remarkable 12-year-old 05.11.2020

How bad will this winter be? Is everything coming up Biogen? And who's going to be president on Jan. 20? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. First, STAT's Helen Branswell joins us to discuss what the winter has in store for the ongoing Covid-19 pandemic. Then, we discuss the latest surprising twist in Biogen’s quest to win FDA approval...

Episode 135: Pfizer's Covid-19 mystery, Ashish Jha on pandemic response, & STAT turns 5 29.10.2020

When are we getting Covid-19 vaccine data? Will concerts ever be safe again? And what's a "Bionomy"?

Episode 134: Erik Gordon on SPACs, plus Covid-19 vaccines, & Biogen's case in Alzheimer's 22.10.2020

Who's voice rings loudest at the FDA? Is it wise to give hedge funds a blank check? And how will the Biogen saga end?

Episode 133: A week of pauses, pharma’s statehouse spending, & how HBCUs approach Covid-19 trials 15.10.2020

Is your local lawmaker flush with pharma cash? How does racism in medicine loom over Covid-19 studies? And who decides when a clinical trial goes on pause?

Episode 132: How Trump's case of Covid-19 affects biotech, medicine, and the FDA with George Scangos 08.10.2020

Why is the president making drug ads? Are antibodies the new vaccines? And is it ethical for doctors to talk about President Trump's health?

Episode 131: Saad Omer on Covid-19 vaccine trials, & Ethan Weiss on intermittent fasting 01.10.2020

Can an itchy arm ruin a clinical trial? Does intermittent fasting work? And is pharma more trustworthy than the CDC?

Episode 130: A road map for Covid-19, the gold rush in health tech, & D.C.'s pandemic unrest 24.09.2020

Is superspreading an Olympic event? Will Covid-19 forever change health tech? And what are the limits of Anthony Fauci's patience?

Episode 129: Heidi Tworek on pandemic PR, plus the CDC's credibility crisis & a lightning round 17.09.2020

How should governments talk about Covid-19? Can the Centers for Disease Control and Prevention rebuild public trust? And when is a steak worth $21 billion?

Episode 128: AstraZeneca’s Covid-19 vaccine, coronavirus politics, & STAT’s Health Tech Summit 10.09.2020

Is AstraZeneca’s Covid-19 vaccine in jeopardy? Why can’t politicians and scientists in Washington get along? Did you miss STAT’s first-ever Health Tech Summit?

Episode 127: Eric Topol on Stephen Hahn, plus Covid-19 vaccine timelines, & the 2000th First Opinion 03.09.2020

Should the FDA commissioner resign? How fast can vaccine trials move? And what do Chelsea Clinton and Chuck Grassley have in common?

Episode 126: The FDA's chaotic week, Trump's effect on science, and Musk's big reveal 27.08.2020

Can the Food and Drug Administration survive Trump? Are drug reviewers in the deep state? And what can Elon Musk teach us about the nature of reality?

Escucha el podcast The Readout Loud en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos